Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

Inclusion Criteria: * Age between 18 and 65 years; * Diagnosed with type 1 diabetes mellitus with a disease duration of more than 5 years; * Glycated hemoglobin (HbA1c) ≤ 7.5% at screening; * Diagnosed with diabetic nephropathy; * UACR between 30 and 300 and eGFR ≥ 60 ml/min/1.73 m². Exclusion Criteria: * Other types of diabetes; * Use of any antidiabetic medications (excluding insulin) within 1 month prior to screening; * History of diabetic ketoacidosis within 3 months prior to screening, or a diagnosed episode of diabetic ketoacidosis within the past 1 month; * History of poor blood glucose control requiring hospitalization (due to hyperglycemia or hypoglycemia) within 1 month prior to screening; * Frequent severe hypoglycemia or unconscious hypoglycemia (more than once requiring medical intervention or emergency care) within 1 month prior to screening; * Use of SGLT2 inhibitors or other renal protective medications within 6 months prior to screening; * Women who are planning to become pregnant, pregnant, or breastfeeding; * Cardiovascular disease (within 6 months prior to screening); * Unstable/rapidly progressing renal disease (within 6 months prior to screening), or renal artery stenosis; * Major liver disease or malignant tumors (within 5 years prior to screening).